State of Wyoming Has $212,000 Stake in Abbott Laboratories $ABT

State of Wyoming cut its stake in Abbott Laboratories (NYSE:ABT) by 75.6% in the third quarter, Holdings Channel.com reports. The firm owned 1,585 shares of the healthcare product maker’s stock after selling 4,908 shares during the quarter. State of Wyoming’s holdings in Abbott Laboratories were worth $212,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Brighton Jones LLC grew its holdings in shares of Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after buying an additional 4,755 shares in the last quarter. Sivia Capital Partners LLC raised its holdings in shares of Abbott Laboratories by 3.5% in the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after purchasing an additional 162 shares during the last quarter. Yarger Wealth Strategies LLC lifted its position in shares of Abbott Laboratories by 13.4% in the second quarter. Yarger Wealth Strategies LLC now owns 3,076 shares of the healthcare product maker’s stock worth $418,000 after purchasing an additional 363 shares in the last quarter. M3 Advisory Group LLC boosted its holdings in Abbott Laboratories by 20.2% during the second quarter. M3 Advisory Group LLC now owns 1,858 shares of the healthcare product maker’s stock worth $253,000 after purchasing an additional 312 shares during the last quarter. Finally, Genesee Capital Advisors LLC grew its position in Abbott Laboratories by 4.6% in the second quarter. Genesee Capital Advisors LLC now owns 8,567 shares of the healthcare product maker’s stock valued at $1,165,000 after purchasing an additional 374 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insiders Place Their Bets

In other news, Director Daniel J. Starks bought 10,000 shares of the company’s stock in a transaction dated Wednesday, February 4th. The stock was bought at an average price of $108.73 per share, with a total value of $1,087,300.00. Following the completion of the acquisition, the director owned 6,738,817 shares of the company’s stock, valued at $732,711,572.41. This represents a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 0.46% of the stock is owned by insiders.

Abbott Laboratories Price Performance

Shares of ABT opened at $111.11 on Tuesday. The company’s 50-day moving average is $120.52 and its 200-day moving average is $126.80. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24. The firm has a market capitalization of $193.21 billion, a PE ratio of 29.87, a PEG ratio of 1.76 and a beta of 0.75. Abbott Laboratories has a fifty-two week low of $105.27 and a fifty-two week high of $141.23.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The business had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. During the same quarter in the prior year, the business earned $1.34 EPS. Abbott Laboratories’s quarterly revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Thursday, January 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Thursday, January 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. Abbott Laboratories’s payout ratio is currently 67.74%.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Argus cut their price target on shares of Abbott Laboratories from $150.00 to $140.00 in a research report on Tuesday, January 27th. Raymond James Financial reduced their price target on Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Weiss Ratings lowered Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 26th. Oppenheimer cut their price objective on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Finally, Royal Bank Of Canada lowered their target price on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $137.05.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.